GlassScriptPhysician profile
Jason E Hershberger
NPI 1598712283
$7,954.84
in general payments reported to CMS, 2019-2025
18 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 91% of Forensic Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $1,190 · 2021: $1,398 · 2022: $925 · 2023: $1,269 · 2024: $1,130 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,734.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,473.28 | 2019-2025 | Invega Sustenna |
| Alkermes, INC. | $1,357.14 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $1,200.73 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,164.01 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $913.25 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $862.73 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Bioxcel Therapeutics, INC. | $324.59 | 2023-2024 | Igalmi |
| Sunovion Pharmaceuticals INC. | $232.12 | 2019-2021 | |
| Abbvie INC. | $88.11 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $76.36 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $54.87 | 2025 | Cobenfy |
| Indivior INC. | $45.71 | 2019-2023 | Perseris |
| Janssen Scientific Affairs, LLC | $41.23 | 2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.79 | 2020-2024 | Caplyta |
| Corium, LLC | $23.23 | 2023 | Azstarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $22.00 | 2022 | |
| Allergan, INC. | $20.84 | 2019 | |
| Luye Pharma (USA) LTD. | $17.85 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hershberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.